Stock KLY KALYTERA THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up

News Kalytera Therapeutics Inc Toronto S.E.

Equities

KLY

CA48349P1036

End-of-day quote Toronto S.E.
Other stock markets
 		5-day change 1st Jan Change
- PTS -.--% Intraday chart for Kalytera Therapeutics Inc -.--% -.--%
2021 Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107 MT
2021 Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107
MT
Claritas Pharmaceuticals : IIROC Trading Resumption - CLAS
AQ
Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107
GL
Claritas Pharmaceuticals : IIROC Trading Halt - CLAS
AQ
Claritas Announces Grant of Stock Options to Directors and Officers
GL
Claritas Pharmaceuticals : Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107
AQ
Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107
CI
Reverse Split: 1 of 20
FA
Claritas Pharmaceuticals : Reports Additional Data in Animal Model of Pulmonary Arterial Hypertension Treatment, R-107
MT
Claritas Pharmaceuticals, Inc. Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease
CI
Claritas Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease
GL
Claritas Pharmaceuticals : 1-For-20 Share Consolidation Effective July 23
MT
Claritas Announces Effective Date for Share Consolidation
GL
Claritas Pharmaceuticals, Inc.(TSXV:CLAS) dropped from S&P/TSX Venture Composite Index
CI
Claritas Pharmaceuticals : Announces Commitments from Company's Largest Shareholders to Vote for Approval of Share Consolidation
AQ
Claritas Announces Commitments from Company’s Largest Shareholders to Vote for Approval of Share Consolidation
GL
Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics
GL
Claritas Pharmaceuticals : Announces Settlement of Debt Transaction
AQ
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Claritas Pharmaceuticals Issues Letter to Shareholders
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLAS.H Stock
  4. KLY Stock
  5. News Kalytera Therapeutics Inc